Truist Securities analyst Joon Lee maintains Cormedix (NASDAQ:CRMD) with a Buy and lowers the price target from $14 to $12.
- Headlines
- Truist Securities Maintains Buy on Cormedix, Lowers Price Target to $12
Truist Securities Maintains Buy on Cormedix, Lowers Price Target to $12
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Latest
17:01
There are 474 national-level public service points for intellectual property information in China.
17:01
The Shanghai Stock Exchange and the Shenzhen Stock Exchange have issued a notice regarding the stock market closures for certain holidays in 2025.
17:01
The FTSE Malaysia Exchange Index increased by 0.3%, closing at 1596.20 points.